| The urokinase‐type plasminogen activator system in cancer metastasis: a review PA Andreasen, L Kjøller, L Christensen, MJ Duffy International journal of cancer 72 (1), 1-22, 1997 | 2132 | 1997 |
| Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful? MJ Duffy Clinical chemistry 47 (4), 624-630, 2001 | 1031 | 2001 |
| National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers CM Sturgeon, MJ Duffy, UH Stenman, H Lilja, N Brunner, DW Chan, ... Clinical chemistry 54 (12), e11-e79, 2008 | 838* | 2008 |
| Metalloproteinases: role in breast carcinogenesis, invasion and metastasis MJ Duffy, TM Maguire, A Hill, E McDermott, N O'Higgins Breast cancer research 2, 1-6, 2000 | 806 | 2000 |
| Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients MP Look, WLJ Van Putten, MJ Duffy, N Harbeck, IJ Christensen, ... Journal of the National Cancer Institute 94 (2), 116-128, 2002 | 783 | 2002 |
| Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use MJ Duffy, A van Dalen, C Haglund, L Hansson, E Holinski-Feder, ... European journal of cancer 43 (9), 1348-1360, 2007 | 662 | 2007 |
| Serum tumor markers in breast cancer: are they of clinical value? MJ Duffy Clinical chemistry 52 (3), 345-351, 2006 | 597 | 2006 |
| Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM) MJ Duffy, N Harbeck, M Nap, R Molina, A Nicolini, E Senkus, F Cardoso European journal of cancer 75, 284-298, 2017 | 578 | 2017 |
| Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines MJ Duffy, A van Dalen, C Haglund, L Hansson, R Klapdor, R Lamerz, ... European journal of cancer 39 (6), 718-727, 2003 | 567 | 2003 |
| Survivin: a new target for anti-cancer therapy BM Ryan, N O’Donovan, MJ Duffy Cancer treatment reviews 35 (7), 553-562, 2009 | 558 | 2009 |
| The urokinase plasminogen activator system: role in malignancy MJ Duffy Current pharmaceutical design 10 (1), 39-49, 2004 | 549 | 2004 |
| The role of proteolytic enzymes in cancer invasion and metastasis MJ Duffy Clinical & experimental metastasis 10, 145-155, 1992 | 494 | 1992 |
| Tumor markers in breast cancer–European Group on Tumor Markers recommendations R Molina, V Barak, A van Dalen, MJ Duffy, R Einarsson, M Gion, H Goike, ... Tumor Biology 26 (6), 281-293, 2005 | 489 | 2005 |
| Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report MJ Duffy, C Sturgeon, R Lamerz, C Haglund, VL Holubec, R Klapdor, ... Annals of oncology 21 (3), 441-447, 2010 | 465 | 2010 |
| Proteases as prognostic markers in cancer. MJ Duffy Clinical cancer research: an official journal of the American Association …, 1996 | 464 | 1996 |
| Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update MJ Duffy, R Lamerz, C Haglund, A Nicolini, M Kalousová, L Holubec, ... International journal of cancer 134 (11), 2513-2522, 2014 | 450 | 2014 |
| Cancer invasion and metastasis: changing views MJ Duffy, PM McGowan, WM Gallagher The Journal of pathology 214 (3), 283-293, 2008 | 433 | 2008 |
| Prognostic and predictive biomarkers in breast cancer: Past, present and future A Nicolini, P Ferrari, MJ Duffy Seminars in cancer biology 52, 56-73, 2018 | 432 | 2018 |
| Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer MJ Duffy, D Reilly, C O'Sullivan, N O'Higgins, JJ Fennelly, P Andreasen Cancer research 50 (21), 6827-6829, 1990 | 421 | 1990 |
| CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use MJ DUFFY, JM BONFRER, J Kulpa, GJS Rustin, G Soletormos, GC Torre, ... International Journal of Gynecologic Cancer 15 (5), 2005 | 420 | 2005 |
